Cancer Therapeutics Insights Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non – Small Cell Lung Cancer ( Including Squamous Cell Carcinomas ) and Wild-Type EGFR or Resistant Mutations

Preclinical data suggest that combined EGF receptor (EGFR) targeting with an EGFR tyrosine kinase inhibitor and an anti-EGFR monoclonal antibody may be superior over single-agent targeting. Therefore, as part of a phase I study,we analyzed the outcome of 20 patientswith non–small cell lung cancer treatedwith the combination of erlotinib and cetuximab. EGFR… CONTINUE READING